Features, pricing, ratings, and pros & cons — compared head-to-head.
360 High-Risk Vulnerability Immunization Tool V2.0 is a commercial endpoint protection platform tool by 360 Security Group (Qihoo 360). Internxt Antivirus is a commercial endpoint protection platform tool by Internxt. Compare features, ratings, integrations, and community reviews side by side to find the best endpoint protection platform fit for your security stack.
Based on our analysis of NIST CSF 2.0 coverage, core features, company size fit, deployment model, here is our conclusion:
360 High-Risk Vulnerability Immunization Tool V2.0
Startups and SMBs with Windows-heavy infrastructure and patching backlogs should run 360 High-Risk Vulnerability Immunization Tool V2.0 first; it immunizes against the specific CVEs that drive ransomware campaigns (MS17-010, CVE-2019-0708) without requiring immediate OS updates. The tool supports Windows 7 through current versions and deploys on-premises, meaning air-gapped networks can actually use it. Skip this if you're looking for NIST PR.PS coverage beyond platform hardening,this tool stops known exploits, not supply chain attacks or firmware-level threats.
Startups and small teams with limited security staff should pick Internxt Antivirus for its native cross-platform coverage without forced enterprise licensing; Windows, Mac, and Linux protection from a single 29-person vendor keeps costs predictable and deployment friction low. The cloud deployment model and direct integration with Internxt Drive mean you're not bolting on another tool to your existing file sync workflow. Skip this if you need endpoint detection and response capabilities or centralized policy enforcement across hundreds of devices; Internxt stops at malware removal and lacks the visibility layer that mid-market teams depend on.
Tool that immunizes Windows systems against critical vulnerabilities
Antivirus software for malware detection and removal on Windows, Mac, and Linux
Access NIST CSF 2.0 data from thousands of security products via MCP to assess your stack coverage.
Access via MCPNo reviews yet
No reviews yet
Explore more tools in this category or create a security stack with your selections.
Common questions about comparing 360 High-Risk Vulnerability Immunization Tool V2.0 vs Internxt Antivirus for your endpoint protection platform needs.
360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..
Internxt Antivirus: Antivirus software for malware detection and removal on Windows, Mac, and Linux. built by Internxt. Core capabilities include Malware detection and removal, Full system scanning, Custom file scanning..
Both serve the Endpoint Protection Platform market but differ in approach, feature depth, and target audience.
360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. Internxt Antivirus differentiates with Malware detection and removal, Full system scanning, Custom file scanning.
360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). Internxt Antivirus is developed by Internxt. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.
360 High-Risk Vulnerability Immunization Tool V2.0 and Internxt Antivirus serve similar Endpoint Protection Platform use cases: both are Endpoint Protection Platform tools, both cover Windows Security. Review the feature comparison above to determine which fits your requirements.
Get strategic cybersecurity insights in your inbox